Egoropal

GIF decision: Withdrawal from market, Marketing prohibition

What does this decision mean?

  • Wycofanie z obrotu — Some of the products covered by the decision were withdrawn from the market — please return them to the pharmacy/distributor.
  • Zakaz wprowadzania — Selected batches are subject to a marketing prohibition — the product cannot be distributed to pharmacies.

A routine FDA inspection revealed serious deficiencies in aseptic manufacturing processes. For a prolonged-release suspension for injection, non-compliance at the sterile manufacturing stage may translate into increased risk to patients' health; a risk to life cannot be excluded. Potential effects: infection, poisoning, severe systemic complications, lack of therapeutic efficacy.

Download the app and stay informed

Get instant notifications about recalled products and protect your family.

Egoropal
Risk Level
Critical
Manufacturer
Egis Pharmaceuticals PLC z siedzibą w Budapeszcie, Węgry
Batch Number
4400718, 4500766, 4501274, 4400293, 4400851, 4500598, 4500832, 4500892, 4501060, 4501376
Notice Date
08.01.2026
View official statement

Related

Other Notices